



SUBOXONE[®] and SUBUTEX[®] APPROPRIATE USE CHECKLIST

Patient Name: _____

As a healthcare provider who prescribes SUBOXONE[®] (buprenorphine and naloxone) sublingual film CIII, SUBOXONE[®] (buprenorphine and naloxone) sublingual tablets CIII, or SUBUTEX[®] (buprenorphine) sublingual tablets CIII, you may find this checklist a useful reminder of the safe use conditions and monitoring requirements to be addressed during each patient's appointment. These include: 1) understanding and reinforcement of safe use conditions, 2) the importance of psychosocial counseling, and 3) screening and monitoring patients to determine progress towards treatment goals.

If a patient continues to abuse various drugs or is unresponsive to treatment, including psychosocial intervention, it is important that you assess the need to refer the patient to a specialist and/or more intensive behavioral treatment environment.

Additional resource: Physician Clinical Support System: <http://pcssb.org/>

Measurement to Ensure Appropriate Use	Intake/ Induction	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7
Date:								
Induction								
Verified patient meets diagnostic criteria for opioid dependence								
Discussed risks described in professional labeling and Medication Guide with patient								
Explained or reviewed conditions of safe storage of medication								
Provided induction doses under appropriate supervision								
Prescribed limited amount of medication at first visit								
Scheduled next visit at interval commensurate with patient stability <ul style="list-style-type: none"> • Weekly, or more frequent visits recommended for the first month 								
Maintenance								
Assessed and encouraged patient to take medication as prescribed <ul style="list-style-type: none"> • Consider pill count/dose reconciliation 								

SUBOXONE® and SUBUTEX® APPROPRIATE USE CHECKLIST

Measurement to Ensure Appropriate Use	Intake/ Induction	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7
Date:								
Maintenance (continued)								
Assessed appropriateness of dosage <ul style="list-style-type: none"> • Suboxone 12 mg to 16 mg is recommended for maintenance • Doses higher than this should be an exception • The need for higher dose should be carefully evaluated 								
Assessed whether patient is receiving the psychosocial support considered necessary								
Assessed whether benefits of treatment with Suboxone outweigh risks associated with Suboxone								
Assessed whether patient is making adequate progress toward treatment goals <ul style="list-style-type: none"> • Conduct urine drug screens as appropriate to assess use of illicit substances • Consider referral to more intensive forms of treatment for patients not making progress 								
Scheduled next visit at interval commensurate with patient stability <ul style="list-style-type: none"> • Weekly, or more frequent visits are recommended for the first month 								

SUBOXONE (buprenorphine and naloxone) sublingual tablets and sublingual film CIII
 SUBUTEX (buprenorphine) sublingual tablets CIII
 SUBOXONE® and SUBUTEX® are registered trademarks of Reckitt Benckiser Healthcare (UK) Ltd.
 1-1283-005-US-1111